Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | NVO |
|---|---|---|
| Founded | 1940 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3B | 269.6B |
| IPO Year | 1995 | N/A |
| Metric | MCD | NVO |
|---|---|---|
| Price | $327.69 | $39.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 11 |
| Target Price | ★ $340.63 | $51.00 |
| AVG Volume (30 Days) | 3.2M | ★ 22.6M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | 2.24% | ★ 3.20% |
| EPS Growth | ★ 4.92 | N/A |
| EPS | ★ 11.95 | N/A |
| Revenue | ★ $26,885,000,000.00 | N/A |
| Revenue This Year | $8.05 | N/A |
| Revenue Next Year | $5.72 | $4.39 |
| P/E Ratio | $27.71 | ★ $13.60 |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $283.47 | $35.85 |
| 52 Week High | $341.75 | $88.55 |
| Indicator | MCD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 32.39 |
| Support Level | $300.13 | N/A |
| Resistance Level | $335.67 | $50.30 |
| Average True Range (ATR) | 5.41 | 0.89 |
| MACD | -0.80 | -0.41 |
| Stochastic Oscillator | 21.51 | 22.96 |
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.